In preclinical models, the combination of anti-LAG-3 and anti-PD1 reduced tumor size and provided a survival benefit, and a recent phase I study using tebotelimab found a partial response in a patient with MPM [55,56]. The gene discussed is LAG3; the disease is neoplasm.